U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

We have hardly begun to understand how inextricably our own health and safety are intertwined with those of our wild ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

While there will no doubt be plenty of competing GLP-1 drugs and weight loss products in the market in the future ... The 10 ...

Source: RBC (Russian Business Consulting), a Russian news outlet, citing Rosalkogoltabakcontrol (the Russian federal service for alcohol market regulation) From January to October, 184.2 million ...

Doctors Without Borders (MSF) and organisations representing people with diabetes picketed outside the offices of insulin ...

nearly five months after the medication was approved in the country. Ozempic, a drug which contains the same active ...

Novo Nordisk has long supplied human insulin pens to the national health department. But last year it decided not to bid for ...

Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on ...